Katia Borgia Barbosa Pagano *

Autora invitada por SIIC

MUTAÇÕES DO BCR-ABL NA (MUTACIONES DEL BCR-ABL EN LA)LEUCEMIA MIELÓIDE CRÔNICA

Estudo retrospectivo multicêntrico latino-americano de avaliação de mutações do (evaluación de mutaciones del) BCR-aBL em pacientes com leucemia mielóide crônica resistentes ao (resistentes al) imatinibe. O presente trabalho demonstrou o (El presente trabajo demostró el) impacto negativo das mutações na sobrevida global e livre de progressão.

*Katia Borgia Barbosa Pagano
describe para SIIC los aspectos relevantes de su trabajo
BCR-ABL MUTATIONS IN CHRONIC MYELOID LEUKEMIA TREATED WITH TYROSINE KINASE INHIBITORS AND IMPACT ON SURVIVAL
Institución principal de la investigación
*University of Campinas (Unicamp), Campinas, Brasil
Imprimir nota

Comprar este artículo
Otros artículos escogidos

Referencias bibliográficas
1. Apperley JF. Part I: Mechanisms of resistance to imatinib in chronicmyeloid leukaemia. Lancet Oncol 8(11):1018-1029, 2007.
2. Corbin AS, La Rosee P, Stoffregen EP, Druker BJ, Deininger MW. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 101(11):4611-4614, 2003.
3. Hochhaus A, Schenk T, Erben P, Ernst T, La Rosee P, Muller MC. Cause and management of therapy resistance. Best Pract Res Clin Haematol 22(3):367-379, 2009.
4. O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronicmyeloid leukemia. Blood 110(7):2242-2249, 2007.
5. Redaelli S, Piazza R, Rostagno R, Magistroni V, Perini P, Marega M, Gambacorti-Passerini C, Boschelli F. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR-ABL mutants. J Clin Oncol 27(3):469-471, 2009.
6. Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, Ossenkoppele GJ, Nicolini FE, O'Brien SG, Litzow M, Bhatia R, Cervantes F, Haque A, Shou Y, Resta DJ, Weitzman A, Hochhaus A, Le Coutre P. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110(10):3540-3546, 2007.
7. Hochhaus A. Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure. Expert Opin Pharmacother 8(18):3257-3264, 2007.
8. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, Muller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saussele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R. European LeukemiaNet recommendations for the management of chronicmyeloid leukemia: 2013. Blood 8;122(6):872-884, 2013.
9. Jabbour E, Hochhaus A, Cortes J, La Rosee P, Kantarjian HM. Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib:Weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history. Leukemia 24(1):6-12, 2010.
10. Branford S, Melo JV, Hughes TP. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: Does the BCR-ABL mutation status really matter? Blood 114(27):5426-5435, 2009.
11. Bengio RM, Riva ME, Moiraghi B, Lanari E, Milone J, Ventriglia V, Bullorsky E, Tezanos Pinto M, Murro H, Bianchini M, Larripa I. Clinical outcome of chronic myeloid leukemia imatinibresistant patients: Do BCR-ABL kinase domain mutations affect patient survival? First multicenter Argentinean study. Leuk Lymphoma 52(9):1720-1726, 2011.
12. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, Apperley J, Cervantes F, Cortes J, Deininger M, Gratwohl A,Guilhot F, Horowitz M, Hughes T, KantarjianH, Larson R, Niederwieser D, Silver R, Hehlmann R. Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108(6):1809-1820, 2006.
13. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J, Hehlmann R. Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 27(35):6041-6051, 2009.
14. Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, Lahaye T, Hanfstein B, Schoch C, Cross NC, Berger U, Gschaidmeier H, Druker BJ, Hehlmann R. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16(11):2190-2196, 2002.
15. Branford S, Rudzki Z,Walsh S, Parkinson I, Grigg A, Szer J, Taylor K, Herrmann R, Seymour JF, Arthur C, Joske D, Lynch K, Hughes T. Detection of BCR-ABLmutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, andmutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 102(1):276-283, 2003.
16. Baccarani M, Castagnetti F, Gugliotta G, Palandri F, Soverini S. Response definitions and European Leukemianet management recommendations. Best Pract Res Clin Haematol 22(3):331-341, 2009.
17. Jabbour E, Kantarjian H, Jones D, Talpaz M, Bekele N, O'Brien S, Zhou X, Luthra R, Garcia-Manero G, Giles F, Rios MB, Verstovsek S, Cortes J. Frequency and clinical significance of BCRABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 20(10):1767-1773, 2006.
18. Nicolini FE, Corm S, Le QH, Sorel N, Hayette S, Bories D, Leguay T, Roy L, Giraudier S, Tulliez M, Facon T, Mahon FX, Cayuela JM, Rousselot P,Michallet M, Preudhomme C, Guilhot F, Roche-Lestienne C. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: A retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). Leukemia 20(6):1061-1066, 2006.
19. Soverini S, Martinelli G, Rosti G, Bassi S, Amabile M, Poerio A, Giannini B, Trabacchi E, Castagnetti F, Testoni N, Luatti S, De Vivo A, Cilloni D, Izzo B, Fava M, Abruzzese E, Alberti D, Pane F, Saglio G, Baccarani M. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: A study by the GIMEMA working party on chronicmyeloid leukemia. J Clin Oncol 23(18):4100-4109, 2005.
20. Jabbour E, Jones D, Kantarjian HM, O'Brien S, Tam C, Koller C, Burger JA, Borthakur G, Wierda WG, Cortes J. Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood 114(10):2037-2043, 2009.
21. Alikian M, Reid AG, Foroni L, Marin D, Druker BJ, O'Hare T, Deininger MW. BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: Frequency and clonal relationships. Blood 121(3):489-498, 2013.
22. Shah NP, Skaggs BJ, Branford S, Hughes TP, Nicoll JM, Paquette RL, Sawyers CL. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest 117(9):2562-2569, 2007.
23. Nicolini FE, Ibrahim AR, Soverini S, Martinelli G, Muller MC, Hochhaus A, Dufva IH, Kim DW, Cortes J, Mauro MJ, Chuah C, Labussiere H, Morisset S, Roche-Lestienne C, Lippert E, Hayette S, Peter S, Zhou W, Maguer-Satta V, Michallet M, Goldman J, Apperley JF, Mahon FX, Marin D, Etienne G. The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis. Haematologica 98(10):1510-1516, 2013.
24. Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A, Iacobucci I, Amabile M, Abruzzese E, Orlandi E, Radaelli F, Ciccone F, Tiribelli M, Di Lorenzo R, Caracciolo C, Izzo B, Pane F, Saglio G, Baccarani M, Martinelli G. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: By the GIMEMA working party on chronic myeloid leukemia. Clin Cancer Res 12(24):7374-7379, 2006.
25. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP, Sawyers CL. Dasatinib in imatinib-resistant Philadelphia chromosomepositive leukemias. N Engl J Med 354(24):2531-2541, 2006.
26. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, Bochinski K, Hochhaus A, Griffin JD, Hoelzer D, AlbitarM, Dugan M, Cortes J, Alland L, Ottmann OG. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl Jmed 354(24):2542-2551, 2006.
27. Ibrahim AR, Clark RE, Holyoake TL, Byrne J, Shepherd P, Apperley JF, Milojkovic D, Szydlo R, Goldman J, Marin D. Secondgeneration tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed. Haematologica 96(12):1779-1782, 2011.

Otros artículos de Katia Borgia Barbosa Pagano

Lima AS, De Mello MR, Fernandes E, Bezerra MF, Oliveira MM, Duarte BK, De Assis RA, Souto FR, Ramos CF, Machado CG, Pagnano K, et al. Clinical outcomes of patients with acute myeloid leukemia: evaluation of genetic and molecular findings in a real-life setting. Blood 126(15):1863-5, 2015.
Pagnano KB, Bendit I, Boquimpani C, et al. Latin American Leukemia Net (LALNET). BCR-ABL mutations in chronic myeloid leukemia treated with tyrosine kinase inhibitors and impact on survival. Cancer Invest 33(9):451-8, 2015.
Sanz MA, Montesinos P, Kim HT, Ruiz-Argüelles GJ, Undurraga MS, Uriarte MR, Martínez L, Jacomo RH, Gutiérrez-Aguirre H, Melo RA, Bittencourt R, Pasquini R, Pagnano K, Fagundes EM et al. IC-APL and PETHEMA and HOVON Groups. All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies. Ann Hematol 94(8):1347-56, 2015.
Ribeiro BF, Vergílio BR, Miranda EC, Almeida MH, Delamain MT, Da Silveira RA, De Souza CA, Albuquerque DM, Dos Santos A, Duarte VO, Oliveira-Duarte GB, Lorand-Metze I, Pagnano KB. BCR-ABL1 transcript levels at 3 and 6 months are better for identifying chronic myeloid leukemia patients with poor outcome in response to second-line second-generation tyrosine kinase inhibitors after imatinib failure: A report from a single institution. Acta Haematologica 134:248-254, 2015.
Lucena-Araujo AR, Kim HT, Jacomo RH, Melo RA, Bittencourt R, Pasquini R, Pagnano K, et al. Prognostic impact of KMT2E transcript levels on outcome of patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukaemia study. British Journal of Haematology (print) 166:540-549, 2014.
Lucena-Araujo AR, Kim HT, Jacomo RH, Melo RA, Bittencourt R, Pasquini R, Pagnano K, Fagundes EM et al. Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study. Ann Hematol 93(12):2001-10, 2014.
Silveira RA, Fachel AA, Moreira YB, De Souza CA, Costa FF, Verjovski-Almeida S, Pagnano KBB. Protein-coding genes and long noncoding RNAs are differentially expressed in dasatinib-treated chronic myeloid leukemia patients with resistance to imatinib. Hematology (Luxembourg. Print) 19:31-41, 2014.
De Almeida MH, Pagnano KBB, Vigorito AC, Lorand-Metze I, De Souza Carmino A. Adherence to tyrosine kinase inhibitor therapy for chronic myeloid leukemia: A Brazilian single-center cohort. Acta Haematologica 130:16-22, 2013.
Rego EM, Kim HT, Ruiz-Argüelles GJ, Undurraga MS, Uriarte Mdel R, Jacomo RH, Gutiérrez-Aguirre H, Melo RA, Bittencourt R, Pasquini R, Pagnano K, et al. Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. Blood (Philadelphia, online) 1:1-41, 2013.
White HE, Hedges J, Bendit I, Branford S, Colomer D, Hochhaus A, Hughes T, Kamel-Reid S, Kim DW, Modur V, Müller MC, Pagnano KB, Pane F, Radich J, Cross NC, Labourier E. Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale. Clin Chem 59(6):938-48, 2013.

Para comunicarse con Katia Borgia Barbosa Pagano mencionar a SIIC como referencia:
kborgia@unicamp.br

---

Acerca del trabajo completo

MUTAÇÕES DO BCR-ABL NA (MUTACIONES DEL BCR-ABL EN LA)LEUCEMIA MIELÓIDE CRÔNICA

Título original en castellano
MUTAÇÕES DO BCR-ABL NA LEUCEMIA MIELOIDE CRÔNICA TRATADA COM INIBIDORES DE TIROSINA QUINASE - IMPACTO NA SOBREVIDA

Autores
Israel Bendit¹, Carla Boquimpani², Carmino Antonio De Souza³, Eliana Miranda⁴, Ilana Zalcberg⁵, Irene Larripa⁶, Luciana Nardinelli⁷, Raquel Bengió⁸
1 Médico, Universidade de São Paulo
2 Médica, Hemorio
3 Médico, Professor Titular
4, Universidade Estadual de Campinas
5 Médica, Instituto Nacional Do Câncer
6, Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina de Buenos Aires
7
8 Médica, Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina de Buenos Aires

Acceso a la fuente original
Cancer Investigation
http://www.tandf.co.uk/journals/titles/07357907.asp

ua40317